Cyclic nucleotide binding domain-containing protein 2 (CNBD2) is a member of the cyclic nucleotide-binding domain (CNBD) family of proteins, characterized by their ability to bind cyclic nucleotides such as cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). These molecules act as second messengers in various signal transduction pathways, translating extracellular signals into a cellular response.The CNBD2 protein, specifically, possesses a domain that is structured to recognize and bind these cyclic nucleotides, leading to a conformational change that typically activates the protein. This activation can have a wide range of downstream effects, depending on the cellular context and the signaling pathways involved. Through its nucleotide-binding capacity, CNBD2 can influence processes such as ion channel regulation, gene transcription, and metabolic regulation.
The particular role of CNBD2 in physiological processes is less well-defined compared to other, more extensively studied CNBD proteins. However, it is hypothesized to be involved in neuronal signaling, given the importance of cyclic nucleotide signaling in the nervous system for functions such as synaptic transmission, plasticity, and neuroprotection. CNBD2 could also have roles in cardiac function, as cAMP and cGMP signaling are critical for regulating heart rate and contractility.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, leading to increased levels of cAMP and cGMP, which may indirectly affect CNBD2. | ||||||
Cilostazol | 73963-72-1 | sc-201182 sc-201182A | 10 mg 50 mg | $109.00 $322.00 | 3 | |
Cilostazol inhibits phosphodiesterase type 3, increasing cAMP levels, which might impact CNBD2 activity. | ||||||
Dipyridamole | 58-32-2 | sc-200717 sc-200717A | 1 g 5 g | $31.00 $102.00 | 1 | |
Dipyridamole inhibits phosphodiesterase and increases cAMP and cGMP levels, potentially affecting CNBD2. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram selectively inhibits phosphodiesterase type 4, leading to increased cAMP levels, possibly influencing CNBD2. | ||||||
BAY 41-2272 | 256376-24-6 | sc-202491 sc-202491A | 5 mg 25 mg | $238.00 $728.00 | 4 | |
BAY 41-2272 activates soluble guanylate cyclase, increasing cGMP levels, potentially impacting CNBD2. | ||||||
Riociguat | 625115-55-1 | sc-476845 | 5 mg | $300.00 | ||
Riociguat stimulates soluble guanylate cyclase, increasing cGMP levels, and might influence CNBD2. | ||||||
Adenosine | 58-61-7 | sc-291838 sc-291838A sc-291838B sc-291838C sc-291838D sc-291838E sc-291838F | 1 g 5 g 100 g 250 g 1 kg 5 kg 10 kg | $34.00 $48.00 $300.00 $572.00 $1040.00 $2601.00 $4682.00 | 1 | |
Adenosine can modulate adenylate cyclase activity, potentially influencing cAMP levels and thereby CNBD2. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone inhibits phosphodiesterase type 3, increasing cAMP levels, potentially impacting CNBD2. | ||||||